Gritstone Oncology, a biotech developing personalized and off-the-shelf cancer immunotherapies, raised $100 million by offering 6.7 million shares at $15, the high end of the range of $13 to $15. The company had originally planned to sell 6.1 million shares. Gritstone Oncology plans to list on the Nasdaq under the symbol GRTS. Goldman Sachs, Cowen and Barclays acted as lead managers on the deal.
